Larimar Therapeutics, Inc.
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania 19004
August 31, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-7553
Re: | Larimar Therapeutics, Inc. |
Registration Statement on Form S-3 |
Filed August 14, 2020 (File No. 333-246370) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the Company) hereby requests that the effective date of the Companys Registration Statement on Form S-3 (File No. 333-246370) (the Registration Statement) be accelerated so that the Companys Registration Statement will become effective at 4:01 PM, Eastern Time, on September 1, 2020, or as soon thereafter as is practicable.
Please contact Rachael M. Bushey, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4331 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]
Very truly yours, | ||||
LARIMAR THERAPEUTICS, INC. | ||||
By: |
/s/ Carole Ben-Maimon | |||
Name: | Carole Ben-Maimon, M.D. | |||
Title: | President and Chief Executive Officer |